immune checkpoint inhibitors

You have access
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance
HARUKA NAKATANI, HAYATO KAWACHI, TADAAKI YAMADA, NAOKI FURUYA, HISASHI TANAKA, AKIHIRO YOSHIMURA, TOMOHIRO OBA, MAKOTO HIBINO, TAKAHITO FUKUDA, YASUHIRO GOTO, AKIRA NAKAO, SHINSUKE OGUSU, YUTA OKAZAKI, TAISHI HARADA, TAKAYO OTA, KEN MASUBUCHI, KOJI MIKAMI, TAE HATA, KENJI MORIMOTO and KOICHI TAKAYAMA

Anticancer Research May 2026, 46 (5) 2789-2806; DOI: https://doi.org/10.21873/anticanres.18159
You have access
Impact of Baseline Body Mass Index on Immunotherapy Outcomes in Patients With Non-small-cell Lung Cancer
DANIEL KREJČÍ, ADAM ŠUBRT, PETR OPÁLKA, JANA KREJČÍ, MONIKA ŠIBALOVÁ, MARTIN SVATOŇ, MILOSLAV PÁLA, PETRA TESAŘOVÁ and NORBERT PAUK

Anticancer Research December 2025, 45 (12) 5579-5586; DOI: https://doi.org/10.21873/anticanres.17892
You have access
Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy
TAKAFUMI FUKUI, SUYA HORI, YUKIHISA HATAKEYAMA, TATSUNORI KIRIU, KANOKO MATSUMURA, NANAKO MIWA, MASAHIRO KATSURADA, KEIKO OKUNO, SHO YOSHIMURA and MOTOKO TACHIHARA

Anticancer Research September 2025, 45 (9) 3859-3875; DOI: https://doi.org/10.21873/anticanres.17745
You have access
Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer
HAN GYEOL KIM, SO YOUNG KANG, KYOUNG-MEE KIM, JI-YEON KIM, YEON HEE PARK, JIN SEOK AHN, YOUNG-HYUCK IM, YOOJOO LIM, SANGHOON SONG, KYUNGHYUN PAENG and EUN YOON CHO

Anticancer Research June 2025, 45 (6) 2575-2586; DOI: https://doi.org/10.21873/anticanres.17629
You have access
Immune Checkpoint Inhibitor-induced Uveitis: Disproportionality and Timing Analyses of the Japanese Pharmacovigilance Database
NAOHITO IDE, KEN-ICHI SAKO and TOMOJI MAEDA

Anticancer Research May 2025, 45 (5) 2215-2223; DOI: https://doi.org/10.21873/anticanres.17595
You have access
Comparative Analysis of Outcomes for Patients With Advanced Renal Cell Carcinoma: Immuno-Oncology Era Versus Tyrosine Kinase Inhibitor Era in the IMDC Favorable-risk Group
HIROKI ISHIHARA, YUKI NEMOTO, SHINSUKE MIZOGUCHI, KOICHI NISHIMURA, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, HIROAKI SHIMMURA, YASUNOBU HASHIMOTO, JUNPEI IIZUKA, TSUNENORI KONDO and TOSHIO TAKAGI

Anticancer Research April 2025, 45 (4) 1643-1652; DOI: https://doi.org/10.21873/anticanres.17545
You have access
Efficacy and Safety of Nivolumab With Ipilimumab in Elderly Patients With Advanced Renal Cell Carcinoma
KOSUKE UEDA, NAOKI ITO, YUYA SAKAI, SATOSHI OHNISHI, TAISHI HIRANO, HIROFUMI KUROSE, KATSUAKI CHIKUI, KEIICHIRO UEMURA, KIYOAKI NISHIHARA, MAKOTO NAKIRI, SHIGETAKA SUEKANE and TSUKASA IGAWA

Anticancer Research November 2024, 44 (11) 5087-5093; DOI: https://doi.org/10.21873/anticanres.17333
Open Access
Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy
MICHELE DIONESE, DAVIDE BIMBATTI, FRANCESCO PIERANTONI, ELEONORA LAI, ELISA ERBETTA, NICOLÒ CAVASIN, SALIM JUBRAN, UMBERTO BASSO and MARCO MARUZZO

Anticancer Research October 2024, 44 (10) 4379-4386; DOI: https://doi.org/10.21873/anticanres.17267
You have access
Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab
KOHEI HAGIWARA, TAKASHI MATSUKI, TAKURO OKADA, CHIHIRO FUSHIMI, TAKAHITO KONDO, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, KIYOAKI TSUKAHARA, TATSUO MASUBUCHI, YUICHIRO TADA, KAHO MOMIYAMA, RYOHEI YAGUCHI, NOBUHIKO ORIDATE, GO OMURA and TAKU YAMASHITA

Anticancer Research September 2024, 44 (9) 4057-4072; DOI: https://doi.org/10.21873/anticanres.17235
Open Access
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment
YUYA HIRASAWA, YUTARO KUBOTA, EMIKO MURA, RISAKO SUZUKI, TOSHIAKI TSURUI, NANA IRIGUCHI, TOMOYUKI ISHIGURO, RYOTARO OHKUMA, MASAHIRO SHIMOKAWA, HIROTSUGU ARIIZUMI, ATSUSHI HORIIKE, SATOSHI WADA, TOMOTAKE ARIYOSHI, SATORU GOTO, KOJI OTSUKA, MASAHIKO MURAKAMI, YUJI KIUCHI, KIYOSHI YOSHIMURA, ROBERT M. HOFFMAN and TAKUYA TSUNODA

Anticancer Research August 2024, 44 (8) 3397-3407; DOI: https://doi.org/10.21873/anticanres.17160

Main menu

User menu

Search

immune checkpoint inhibitors

Pages